https://www.gsk.com/en-gb/media/press-releases/us-fda-expands-jemperli-dostarlimab-plus-chemotherapy-approval-to-all-adult-patients-with-primary-advanced-or-recurrent-endometrial-cancer/
Jemperli approval now includes MMRp/MSS tumours, which represent majority of endometrial cancer cases.
us fdaexpandsjemperlidostarlimabplus
https://www.pharmaceutical-technology.com/data-insights/dostarlimab-gsk-laryngeal-cancer-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-274104&utm_campaign=recommended-articles-pi
Dostarlimab is under clinical development by GSK and currently in Phase III for Laryngeal Cancer.
laryngeal cancerdostarlimabgsklikelihoodapproval
https://www.pharmaceutical-technology.com/data-insights/dostarlimab-gsk-vulvar-cancer-likelihood-of-approval/
Dostarlimab is under clinical development by GSK and currently in Phase II for Vulvar Cancer.
vulvar cancerdostarlimabgsklikelihoodapproval
https://www.outlookindia.com/international/dostarlimab-vanishes-cancer-miraculously-in-patients-for-first-time-in-medical-history-news-200968
Dostarlimab, a drug was given in a small clinical trial to 18 patients for around six months, and in the end, it was found that cancer had just vanished away...
first timedostarlimabcancermiraculouslypatients
https://www.pharmaceutical-technology.com/data-insights/dostarlimab-gsk-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-216318&utm_campaign=recommended-articles-pi
Dostarlimab is under clinical development by GSK and currently in Phase II for Pancreatic Ductal Adenocarcinoma.
dostarlimabgskpancreaticadenocarcinomalikelihood
https://www.pharmaceutical-technology.com/data-insights/dostarlimab-gsk-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/
Dostarlimab is under clinical development by GSK and currently in Phase III for Head And Neck Squamous Cell Carcinoma (HNSC).
squamous cell carcinomadostarlimabgskheadneck
https://www.pharmaceutical-technology.com/data-insights/dostarlimab-gsk-hepatocellular-carcinoma-likelihood-of-approval/
Dostarlimab is under clinical development by GSK and currently in Phase II for Hepatocellular Carcinoma.
hepatocellular carcinomadostarlimabgsklikelihoodapproval